HEALTH

CHPA to Hoosier State: E-tracking will curb PSE sales

BY Michael Johnsen

WASHINGTON The Consumer Healthcare Products Association is slated to testify Wednesday before an Indiana legislative committee on how the state can improve its policies for preventing the illegal diversion of pseudoephedrine.

The Indiana State Legislature’s Criminal Law and Sentencing Policy Study Committee will hear a range of policy options, from requiring a prescription for currently accessible medicines to implementing an electronic tracking system to block illegal sales of PSE.

“The residents of Indiana deserve a solution that will help fight the state’s meth problem, without placing additional burdens on individuals, families and the state,” stated Mandy Hagan, director of state government relations for CHPA. “Electronic tracking is the only system that blocks illegal PSE sales while maintaining consumer access to the safe and effective medications they rely on for colds and allergies.”

In Indiana, there currently is no mechanism in place to curb the practice of “smurfing,” when criminals move from store to store to purchase illegal amounts of PSE to be used in the production of meth.

E-tracking, which has been adopted by 12 states nationwide and is funded by members of CHPA, will afford local law enforcement officials an investigative tool to track and prevent meth production across state lines. The system also preserves Indianans’ over-the-counter access to the PSE medications.

According to a poll by David Binder Research, almost two-thirds of surveyed Indiana voters oppose making common cold and allergy medications containing PSE available by prescription only, and 82% agree that an Rx-only requirement would create an “unnecessary burden” for law-abiding citizens.

The Indiana State Retail Association also supports implementation of an electronic tracking system.

The survey, conducted from Jan. 14 to 24, involved 368 Indiana state residents ages 18 years or over, all of whom voted in the last election, and has a margin of error of +/-5.1%. The survey was sponsored by CHPA.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Bayer Consumer Care adds two products to One A Day line

BY Michael Johnsen

MORRISTOWN, N.J. Bayer Consumer Care on Tuesday introduced two new gender-specific multivitamins: One A Day Menopause Formula and One A Day Men’s Pro Edge.

 

One A Day Menopause Formula is a complete multivitamin formulated with soy isoflavones to help address hot flashes and mild mood changes.

 

"It can often be a challenge for women going through this new life stage to get the nutrients they need," stated diet and nutrition expert Madelyn Fernstrom. "Even with a healthy diet, supplementation may be needed to get adequate amounts of the nutrients important to this age group, particularly vitamin D and calcium. This can help support a healthy lifestyle for women as they enter this stage of their lives."

In addition, women going through menopause now have a new resource for information. LiveMenopause.com is dedicated to providing information about menopause and connecting women to others who are going through this stage of life.

 

Meanwhile, One A Day Men’s Pro Edge is a complete multivitamin that contains high levels of magnesium and vitamins A, B, C and E.

 

 

"Because men who are physically active exert more energy, they have an increased need for some nutrients to help their bodies refuel," Fernstrom said. "Though diet is the first source for nutritional needs, supplementation with a multivitamin can help provide extra nutrients to support optimal health for the busy, active man."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Decision Resources: Market for Alzheimer’s disease drugs will expand

BY Alaric DeArment

BURLINGTON, Mass. Biotech drugs for treating Alzheimer’s disease will more than triple the size of the market in several key countries over the next decade, according to a new report by industry research company Decision Resources.

The report showed that bapineuzumab, made by Johnson & Johnson and Pfizer, and Eli Lilly’s solanezumab will drive the market for Alzheimer’s drugs from 2009’s $4.3 billion to $13.3 billion in 2019 in the United States, Japan, the United Kingdom, Germany, France, Italy and Spain.

Whereas most current Alzheimer’s drugs are acetylcholinesterase inhibitors, or AChEIs, which treat the disease’s cognitive symptoms without modifying its course, the new drugs have the potential to slow the rate of neural degeneration and cognitive decline, according to the report. Still, sales of AChEIs will remain strong through the decade.

“Despite increased generic competition and the launch of more-expensive and potentially more-efficacious therapies, AChEI sales will be buoyed through 2019,” Decision Resources director Bethany Kiernan said. “This will be largely due to an overall market expansion driven by increases in the number of drug-treated patients but also, to a lesser extent, by the launch of new formulations of branded AChEIs.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?